Zhang, J.-Q.; Li, R.; Dong, X.-Y.; He, N.; Yin, R.-J.; Yang, M.-K.; Liu, J.-Y.; Yu, R.-L.; Zhao, C.-Y.; Jiang, T. Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors. Int. J. Mol. Sci.2022, 23, 2199.
Zhang, J.-Q.; Li, R.; Dong, X.-Y.; He, N.; Yin, R.-J.; Yang, M.-K.; Liu, J.-Y.; Yu, R.-L.; Zhao, C.-Y.; Jiang, T. Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors. Int. J. Mol. Sci. 2022, 23, 2199.
Zhang, J.-Q.; Li, R.; Dong, X.-Y.; He, N.; Yin, R.-J.; Yang, M.-K.; Liu, J.-Y.; Yu, R.-L.; Zhao, C.-Y.; Jiang, T. Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors. Int. J. Mol. Sci.2022, 23, 2199.
Zhang, J.-Q.; Li, R.; Dong, X.-Y.; He, N.; Yin, R.-J.; Yang, M.-K.; Liu, J.-Y.; Yu, R.-L.; Zhao, C.-Y.; Jiang, T. Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors. Int. J. Mol. Sci. 2022, 23, 2199.
Abstract
Hyperactivation of Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling is an attractive therapeutic target for tumor therapy. Herein, forty-eight novel meridianin derivatives were designed and synthesized, and their anti-tumor activity were evaluated in vitro both for activity optimization and structure-activity relationship (SAR) study. The results indicated that most derivatives exhibited significantly improved anti-tumor activity, especially for compound 6e. The compound 6e contains an isothiouronium linked by an alkyl chain consisting of 6 carbon atoms with IC50 ranging from 1.11 to 2.80 μM on various cancer cell lines. Consistently, 6e dose dependently induced the apoptosis of A549 and DU145 cells, in which STAT3 are constitutively active. Western blotting assays indicated that the phosphorylation levels of JAK1, JAK2 and STAT3 were inhibited by 6e at 5 μM without significant change in total STAT3 level. Moreover, 6e also suppressed the expressions of STAT3 downstream genes, including c-Myc, Cyclin D1 and Bcl-XL at 10 μM. An additional in vivo study revealed that 6e at the dose of 10 mg/kg could potently inhibit the DU145 xenograft tumor without obvious body-weight loss. These results clearly indicate that 6e could be a potential anti-tumor agent by targeting JAK/STAT3 signaling pathway.
Chemistry and Materials Science, Medicinal Chemistry
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
